Leerink Partners on Enhabit Home Health & Hospice (EHAB): 'Very Modest EBITDA Beat with 2025 Guidance Mostly In-Line'
Leerink Partners analyst Whit Mayo reiterated a Market Perform rating on Enhabit Home Health & Hospice (NYSE: EHAB).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)